Differential inhibition of lamivudine-resistant hepatitis B virus by allele-specific RNAi

Journal of Virological Methods

Volumn 168, Issue 1-2, 2010, Pages 6-12

  Teng, Xu ^a,b,c   Xu, Wei Zhen ^a,b,c   Hao, Mei Li ^a,b,c   Fang, Yong ^a,b,c   Zhao, Ying Xin ^a,b,c   Chen, Si Jia ^a,b,c   Li, Di ^a,b,c   Gu Hong Xi, H X ^a,b,c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Heilongjiang Provincial Key Laboratory for Infection and Immunity   (China)

^c Key Lab of Heilongjiang Province Education Bureau for Etiology   (China)

Author keywords

ASP RNAi; Hepatitis B virus; Lamivudine resistant mutant

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; SMALL INTERFERING RNA; ANTIVIRUS AGENT; CULTURE MEDIUM;

ANTIBIOTIC RESISTANCE; ANTIBODY PRODUCTION; ARTICLE; BASE MISPAIRING; CELL CULTURE; CELL LINE; CELL STRAIN HEPG2; CONTROLLED STUDY; EUKARYOTE; GENE EXPRESSION; GENETIC TRANSFECTION; HEPATITIS B VIRUS; NONHUMAN; PLASMID; PRIORITY JOURNAL; RNA INTERFERENCE; SUPERNATANT; VIRUS INHIBITION; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; CHEMISTRY; CULTURE MEDIUM; DRUG EFFECTS; GENE SILENCING; GENETICS; HUMAN; LIVER CELL; METABOLISM; VIROLOGY; VIRUS GENE;

EUKARYOTA; HEPATITIS B VIRUS;

ANTIVIRAL AGENTS; CELL LINE; CULTURE MEDIA; DRUG RESISTANCE, VIRAL; GENE SILENCING; GENES, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; LAMIVUDINE; RNA, SMALL INTERFERING; VIRUS REPLICATION;

EID: 77955093371     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2010.04.007     Document Type: Article

References (31)

1. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., Brown N., Condreay L.D. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27:1670-1677.
2. Allerson C.R., Sioufi N., Jarres R., Prakash T.P., Naik N., Berdeja A., Wanders L., Griffey R.H., Swayze E.E., Bhat B. Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem. 2005, 48:901-904.
3. Brunelle M.N., Jacquard A.C., Pichoud C., Durantel D., Carrouee-Durantel S., Villeneuve J.P., Trepo C., Zoulim F. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005, 41:1391-1398.
4. Chen R.Y., Edwards R., Shaw T., Colledge D., Delaney W.E.t., Isom H., Bowden S., Desmond P., Locarnini S.A. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003, 37:27-35.
5. Chen Y., Cheng G., Mahato R.I. RNAi for treating hepatitis B viral infection. Pharm. Res. 2008, 25:72-86.
6. Denovan-Wright E.M., Davidson B.L. RNAi: a potential therapy for the dominantly inherited nucleotide repeat diseases. Gene Ther. 2006, 13:525-531.
7. Ding H., Schwarz D.S., Keene A., Affar el B., Fenton L., Xia X., Shi Y., Zamore P.D., Xu Z. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell 2003, 2:209-217.
8. Doench J.G., Sharp P.A. Specificity of microRNA target selection in translational repression. Genes Dev. 2004, 18:504-511.
9. Elbashir S.M., Martinez J., Patkaniowska A., Lendeckel W., Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 2001, 20:6877-6888.
10. Giladi H., Ketzinel-Gilad M., Rivkin L., Felig Y., Nussbaum O., Galun E. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol. Ther. 2003, 8:769-776.
11. Haley B., Zamore P.D. Kinetic analysis of the RNAi enzyme complex. Nat. Struct. Mol. Biol. 2004, 11:599-606.
12. Hamasaki K., Nakao K., Matsumoto K., Ichikawa T., Ishikawa H., Eguchi K. Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett. 2003, 543:51-54.
13. Hoerter J.A., Walter N.G. Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum. RNA 2007, 13:1887-1893.
14. Jackson A.L., Bartz S.R., Schelter J., Kobayashi S.V., Burchard J., Mao M., Li B., Cavet G., Linsley P.S. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 2003, 21:635-637.
15. Kao J.H., Chen D.S. Global control of hepatitis B virus infection. Lancet Infect. Dis. 2002, 2:395-403.
16. Lau J.Y., Wright T.L. Molecular virology and pathogenesis of hepatitis B. Lancet 1993, 342:1335-1340.
17. Lee W.M. Hepatitis B virus infection. N. Engl. J. Med. 1997, 337:1733-1745.
18. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
19. Locarnini S., McMillan J., Bartholomeusz A. The hepatitis B virus and common mutants. Semin. Liver Dis. 2003, 23:5-20.
20. Mallory A.C., Reinhart B.J., Jones-Rhoades M.W., Tang G., Zamore P.D., Barton M.K., Bartel D.P. MicroRNA control of PHABULOSA in leaf development: importance of pairing to the microRNA 5' region. EMBO J. 2004, 23:3356-3364.
21. Matthews G.V., Bartholomeusz A., Locarnini S., Ayres A., Sasaduesz J., Seaberg E., Cooper D.A., Lewin S., Dore G.J., Thio C.L. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006, 20:863-870.
22. McCaffrey A.P., Nakai H., Pandey K., Huang Z., Salazar F.H., Xu H., Wieland S.F., Marion P.L., Kay M.A. Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol. 2003, 21:639-644.
23. Miller V.M., Xia H., Marrs G.L., Gouvion C.M., Lee G., Davidson B.L., Paulson H.L. Allele-specific silencing of dominant disease genes. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:7195-7200.
24. Ohnishi Y., Tamura Y., Yoshida M., Tokunaga K., Hohjoh H. Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi. PLoS One 2008, 3:e2248.
25. Radziwill G., Tucker W., Schaller H. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J. Virol. 1990, 64:613-620.
26. Rodriguez-Lebron E., Paulson H.L. Allele-specific RNA interference for neurological disease. Gene Ther. 2006, 13:576-581.
27. Schwarz D.S., Ding H., Kennington L., Moore J.T., Schelter J., Burchard J., Linsley P.S., Aronin N., Xu Z., Zamore P.D. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet. 2006, 2:e140.
28. Shlomai A., Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology 2003, 37:764-770.
29. Stuyver L.J., Locarnini S.A., Lok A., Richman D.D., Carman W.F., Dienstag J.L., Schinazi R.F. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001, 33:751-757.
30. Sun D., Nassal M. Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus. J. Hepatol. 2006, 45:636-645.
31. Xu W.Z., Fang Y., Li D., Wang Y., Shang Q.L., Li G.Q., Teng X., Gu H.X. Construction and expression of eukaryotic plasmids containing lamivudine-resistant or wild-type strains of hepatitis B virus genotype C. World J. Gastroenterol. 2008, 14:3733-3738.